Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Osteitis Deformans × Trastuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 493 Stomach Neoplasms 54 Neoplasm Metastasis 46 Neoplasms 31 HER2-positive Breast Cancer 26 Breast Neoplasms, Male 26 Colorectal Neoplasms 23 Esophageal Neoplasms 19 Brain Neoplasms 19 Carcinoma, Non-Small-Cell Lung 17 Inflammatory Breast Neoplasms 15 Triple Negative Breast Neoplasms 11 Pancreatic Neoplasms 10 Endometrial Neoplasms 9 Colonic Neoplasms 9 Rectal Neoplasms 8 Ovarian Neoplasms 8 Adenocarcinoma Of Esophagus 7 Adenocarcinoma 7 Urinary Bladder Neoplasms 6 Sarcoma 6 Salivary Gland Neoplasms 6 Prostatic Neoplasms 6 Pathologic Complete Response 6 Lung Neoplasms 6 Gallbladder Neoplasms 6 Biliary Tract Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Breast Diseases 5 Recurrence 4

Interventions

Lapatinib 2 ribociclib 1 delta 24-sterol reductase 1 Trastuzumab 1 Paclitaxel 1 Magnetic Resonance Spectroscopy 1 Letrozole 1 Goserelin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00553358 2021-09-21

Neo ALTTO

Novartis

Phase 3 Completed

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

Data powered by HemOnc (CC BY 4.0) Colophon ⚡